Mignon D J M van Gent
Overview
Explore the profile of Mignon D J M van Gent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Zelisse H, van Gent M, Mom C, de Ridder S, Snijders M, Heeling M, et al.
Ann Diagn Pathol
. 2024 Nov;
74:152411.
PMID: 39591762
Fundamental and translational research in ovarian cancer aims to enhance understanding of disease mechanisms and improve treatment and survival outcomes. To support this, we established the Dutch multicenter, interdisciplinary Archipelago...
3.
Zelisse H, Dijk F, van Gent M, Hooijer G, Mom C, van de Vijver M, et al.
Hum Pathol
. 2024 Jul;
151:105631.
PMID: 39084566
To improve the precision of epithelial ovarian cancer histotyping, Köbel et al. (2016) developed immunohistochemical decision-tree algorithms. These included a six- and four-split algorithm, and separate six-split algorithms for early-...
4.
Zelisse H, de Ridder S, van Gent M, Mom C, Wisman G, Roes E, et al.
Biopreserv Biobank
. 2024 Apr;
22(6):568-577.
PMID: 38682281
Biobanks play a crucial role in fundamental and translational research by storing valuable biomaterials and data for future analyses. However, the design of their information technology (IT) infrastructures is often...
5.
Zelisse H, Hwan R, van de Vijver M, Dijk F, Mom C, Hooijer G, et al.
Virchows Arch
. 2024 Apr;
486(2):381-391.
PMID: 38622323
High-grade serous ovarian carcinoma (HGSOC) can be categorized into four gene expression-based subtypes, with supposedly distinct prognoses and treatment responses. Murakami et al. translated these gene expression-based subtypes into the...
6.
Aronson S, Lopez-Yurda M, Koole S, Schagen van Leeuwen J, Schreuder H, Hermans R, et al.
Lancet Oncol
. 2023 Sep;
24(10):1109-1118.
PMID: 37708912
Background: The OVHIPEC-1 trial previously showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery resulted in improved progression-free and overall survival compared with cytoreductive surgery alone...
7.
Wever B, van den Helder R, van Splunter A, van Gent M, Kasius J, Trum J, et al.
Int J Cancer
. 2023 Mar;
153(2):341-351.
PMID: 36912267
Endometrial cancer incidence is rising and current diagnostics often require invasive biopsy procedures. DNA methylation marker analysis of minimally- and non-invasive sample types could provide an easy-to-apply and patient-friendly alternative...
8.
Lof P, Engelhardt E, van Gent M, Mom C, Rosier-van Dunne F, van Baal W, et al.
Int J Gynecol Cancer
. 2023 Jan;
33(1):74-82.
PMID: 36600495
Objectives: In patients with an ovarian mass, a risk of malignancy assessment is used to decide whether referral to an oncology hospital is indicated. Risk assessment strategies do not perform...
9.
Zelisse H, van Gent M, de Ridder S, van der Aa M, Van Altena A, Bart J, et al.
Gynecol Obstet Invest
. 2022 Nov;
87(6):389-397.
PMID: 36450222
Objectives: Ovarian cancer has the worst overall survival rate of all gynecologic malignancies. For the majority of patients, the 5-year overall survival rate of less than 50% has hardly improved...
10.
Luijten M, Van Weelden W, de Kroon C, Pijnenborg J, van Gent M
Ned Tijdschr Geneeskd
. 2022 Feb;
165.
PMID: 35129891
Background: The incidence of endometrial carcinoma (EC) is rising worldwide due to an increased life expectancy and obesity. Approximately 2% of patients with EC is under the age of 45....